STOCK TITAN

Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Grace Therapeutics (Nasdaq: GRCE) reported a $2.131 million net loss for the three months ended September 30, 2026. Loss per share was $0.11, versus $0.06 a year earlier, when net loss was $938,000. Six-month net loss reached $17.921 million, including a $13.533 million intangible-asset impairment.

An August common-stock private placement raised $10 million, with $9.2 million in net proceeds. Cash totaled $21.311 million at September 30; the company expects funding to sustain planned operations through calendar 2028.

Grace is addressing manufacturing-control and non-clinical items in the FDA's complete response letter for GTx-104. The FDA identified no clinical safety or efficacy deficiencies and requested no additional clinical data. Transfer to a second manufacturer and required non-clinical studies have begun. Resubmission timing depends on which manufacturing pathway reaches readiness first.

Loading...
Loading translation...
9 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point$10 million private placement completed in August, providing $9.2 million net for GTx-104 manufacturing and regulatory work. 26% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway through calendar 2028 is expected by the company, including activities addressing the FDA response letter.
  • Moderate pointFDA identified no clinical safety or efficacy deficiencies for GTx-104 and requested no additional clinical data.
  • Minor pointCash increased to $21.311 million at September 30, 2026, from $16.977 million at March 31, 2026.
  • Minor pointSecond-manufacturer technology transfer began during the quarter, starting with analytical methods; required non-clinical studies also began.
4 minor points
  • Minor pointGeneral and administrative expenses fell to $1.407 million from $1.961 million for the quarter, year over year.
  • Minor pointSix-month general and administrative expenses declined to $3.094 million from $4.096 million a year earlier.
  • Minor pointQuarterly operating loss narrowed to $2.292 million from $2.529 million a year earlier.
  • Minor pointTotal liabilities declined to $2.218 million at September 30, 2026, from $2.758 million at March 31, 2026.

Negative

  • Major pointCommon-stock financing diluted holders; outstanding shares rose to 21,035,930 at September 30 from 16,024,026 at March 31, 2026.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.GTx-104 resubmission remains dependent on manufacturing readiness; current-manufacturer reinspection depends on its readiness and FDA scheduling.
  • Moderate pointQuarterly net loss widened to $2.131 million, or $0.11 per share, from $938,000, or $0.06, a year earlier.
  • Moderate pointSix-month net loss widened to $17.921 million, or $0.96 per share, from $4.301 million, or $0.27, a year earlier.
  • Moderate pointOperating cash use was approximately $5.0 million for the six months ended September 30, 2026.
6 minor points
  • Minor point$13.533 million intangible-asset impairment was recorded in the six months ended September 30, 2026, versus none a year earlier.
  • Minor pointQuarterly research and development expenses increased to $885,000 from $568,000 a year earlier, reflecting manufacturing and non-clinical work.
  • Minor pointSix-month research and development expenses increased to $1.582 million from $1.523 million a year earlier.
  • Minor pointPrior-year quarterly warrant valuation gain of $1.427 million did not recur; the applicable warrants expired.
  • Minor pointInterest and other income declined to $154,000 quarterly and $295,000 over six months, versus $172,000 and $375,000 a year earlier.
  • Minor pointStockholders' equity declined to $55.480 million at September 30, 2026, from $63.896 million at March 31, 2026.

News Explained

The report shows common shares outstanding rose from 16,024,026 on March 31, 2026 to 21,035,930 on September 30, 2026; the larger share base dilutes existing holders’ proportionate ownership.

Argus Nov 12 session
-2.43% close to close 0.7x rel. volume Open Argus
Details

News Market Reaction – GRCE

On Nov 12, the day this news came out, GRCE closed 2.43% below the previous close.

Data tracked by StockTitan Argus for the Nov 12 session.

Key Figures

Net loss: $2.1 million Loss per share: $0.11 per share Private placement: $10 million +4 more
Net loss
$2.1 million
Q2 2027; versus $0.9 million in Q2 2026
Loss per share
$0.11 per share
Q2 2027; versus $0.06 per share in Q2 2026
Private placement
$10 million
Completed in August 2026
Net proceeds
$9.2 million
August 2026 private placement
Cash and cash equivalents
$21.3 million
As of September 30, 2026
Operating cash used
Approximately $5.0 million
Six months ended September 30, 2026
Cash runway
Through the end of calendar 2028
Company estimate for planned operations

Previous Earnings Reports

1 past event · Latest: Aug 13
Same Type 1 event
  1. Aug 13

    Q1 earnings

    24h Move
    -1.4%

    Reported a prior-quarter net loss and continued GTx-104 CRL remediation and dual-source manufacturing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

complete response letter, chemistry, manufacturing and controls, new drug application, contract manufacturing organization, +1 more
5 terms
complete response letter regulatory
"FDA's Complete Response Letter (CRL)"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
chemistry, manufacturing and controls regulatory
"chemistry, manufacturing and controls (CMC)"
Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.
new drug application regulatory
"resubmission of its New Drug Application (NDA)"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
contract manufacturing organization technical
"current contract manufacturing organization (CMO)"
A contract manufacturing organization (CMO) is a company that makes drugs, medical devices, or other health products on behalf of another firm, handling production, quality checks and often regulatory paperwork. For investors, CMOs matter because they let product owners scale up or cut costs without large factory investments, but they also concentrate operational and regulatory risk—so a dependable CMO can speed revenue and reduce capital needs, while problems at a CMO can disrupt supply and value.
pharmacokinetic variability medical
"lower inter- and intra-subject pharmacokinetic variability"
Pharmacokinetic variability is the difference in how a drug moves through people’s bodies — how fast it is absorbed, how it spreads, how the body breaks it down, and how it leaves. Like different cars getting different miles per gallon on the same road, this variation affects how well a given dose works and how likely side effects are, so investors watch it because high variability can complicate dosing, slow regulatory approval, require extra testing or monitoring, and influence a drug’s commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PRINCETON, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended September 30, 2026.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “Our dual-source manufacturing strategy to address potential remediation issues at our current contract manufacturer is progressing, and the timing of our NDA resubmission will reflect whichever manufacturing site reaches readiness first. The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission. We look forward to reporting our progress as we work toward achieving these important milestones.”

Second Quarter 2027 and Recent Corporate Highlights

  • Completed a $10 million private placement financing with certain institutional and accredited investors. The Company intends to use the net proceeds from the financing to support the manufacturing and regulatory work needed to advance GTx-104.
  • Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026. The FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The Company is working on its previously disclosed plan to address the identified issues and will report progress as key milestones are achieved.
  • Initiated a dual-source manufacturing strategy for GTx-104 to address potential remediation issues from its current contract manufacturing organization (CMO). The Company’s current CMO has responded to the FDA, submitted a corrective action plan, and, the Company believes, is executing that plan in direct communication with the FDA. Reinspection timing depends on the current CMO’s readiness and FDA scheduling. In parallel, technology transfer was initiated during the quarter ended September 30, 2026 to a second, U.S.-based CMO, starting with analytical method transfer. The Company has also initiated the required non-clinical studies. The NDA resubmission may be supported by either CMO, or both, and its timing will reflect the pathway that reaches readiness first.

Second Quarter 2027 Financial Results

The Company reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, an increase of $1.2 million from the net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025. The increase in net loss was primarily due to a $1.4 million favorable change in the fair value of derivative warrant liabilities recorded during the three months ended September 30, 2025 with no such activity recorded in the three months ended September 30, 2026 as the applicable warrants have expired, as well as an increase in research and development expenses of $0.3 million, offset partially by a $0.6 million decrease in general and administrative expenses.

Total research and development expenses for the three months ended September 30, 2026 were $0.9 million, compared to $0.6 million for the three months ended September 30, 2025. The increase of $0.3 million primarily reflected higher third-party research activities related to the dual-source manufacturing strategy for GTx-104 and the required non-clinical studies identified in the CRL.

General and administrative expenses were $1.4 million for the three months ended September 30, 2026, a decrease of $0.6 million from $2.0 million for the three months ended September 30, 2025. The decrease was primarily the result of a $0.3 million decrease in professional fees primarily related to decreased legal fees, a $0.1 million decrease in pre-commercial planning activities for GTx-104, and a $0.1 million decrease in salaries and benefits.

Cash Runway

As of September 30, 2026, cash and cash equivalents were $21.3 million, a net increase of $4.3 million compared to cash and cash equivalents of $17.0 million at March 31, 2026. Cash used in operations for the six months ended September 30, 2026 was approximately $5.0 million. As announced in August 2026, the Company completed a private placement of its common stock with certain institutional and accredited investors. Net proceeds to the Company were $9.2 million. The Company plans to use its existing cash and cash equivalents towards resolving the items cited in the FDA’s CRL, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations, including the activities to address the items cited in the CRL, through the end of calendar 2028.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients per year.

About GTx-104

GTx-104 is a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.

For more information, please visit: www.gracetx.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including, but not limited to, statements regarding the Company’s cash runway and its planned uses of its existing cash and cash equivalents; the Company’s intended uses of the net proceeds from the August 2026 financing; future prospects of GTx-104; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of the NDA for GTx-104; the Company’s planned approach to addressing the items cited in the CRL; the Company’s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company’s belief that its current contract manufacturer is executing the corrective action plan in direct communication with the FDA; the Company’s plans to complete the required non-clinical studies; the Company’s plans to report progress against key milestones; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the timing and success of any regulatory resubmission of the NDA for GTx-104; (ii) the ability of the Company’s current contract manufacturer to regain compliance and generate the required leachables data, the timing of any FDA reinspection of that contract manufacturer, and that facility’s compliance status, which are determined by the FDA and outside the Company’s control, and the FDA’s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iii) the ability of a second, U.S.-based contract manufacturer to complete the technology transfer, manufacture three registration batches, generate the required 12 months of stability data, analytical data and leachables data, and complete a product-specific pre-approval inspection; (iv) the need to complete additional non-clinical studies; (v) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vi) the Company’s potential need for additional capital, which may not be available on acceptable terms; (vii) changes to regulatory pathways; (viii) the Company’s ability to protect its intellectual property for GTx-104; and (ix) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.

For more information, please contact:

Grace Therapeutics Contact: 
Prashant Kohli 
Chief Executive Officer 
Tel: 609-322-1602 
Email: info@gracetx.com 
www.gracetx.com 
Investor Relations: 
LifeSci Advisors 
Mike Moyer 
Managing Director 
Phone: 617-308-4306 
Email: mmoyer@lifesciadvisors.com 
  

GRACE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)

  September 30, 2026 March 31, 2026 
(Expressed in thousands except share data) $  $ 
Assets      
Current assets:      
Cash and cash equivalents 21,311  16,977 
Receivables 20  20 
Prepaid expenses 629  383 
Total current assets 21,960  17,380 
Equipment, net 5  8 
Intangible assets 27,595  41,128 
Goodwill 8,138  8,138 
Total assets 57,698  66,654 
       
Liabilities and Stockholders’ equity      
Current liabilities:      
Trade and other payables 1,614  2,146 
Total current liabilities 1,614  2,146 
       
Deferred tax liability 604  612 
Total liabilities 2,218  2,758 
       
Commitments and contingencies      
       
Stockholders’ equity:      
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of September 30, 2026 and March 31, 2026 —  — 
Common stock, $0.0001 par value per share; 100,000,000 authorized; 21,035,930 and 16,024,026 shares issued and outstanding as of September 30, 2026 and March 31, 2026, respectively 2  1 
Additional paid-in capital 307,917  298,413 
Accumulated other comprehensive loss (6,038) (6,038)
Accumulated deficit (246,401) (228,480)
Total stockholders’ equity 55,480  63,896 
Total liabilities and stockholders’ equity 57,698  66,654 
       

GRACE THERAPEUTICS, INC.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(Unaudited)

  Three months ended  Six months ended 
  September 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
 
(Expressed in thousands, except share and per share data)            
   $   $   $   $ 
                 
Operating expenses                
Research and development expenses   (885)   (568)   (1,582)   (1,523)
General and administrative expenses   (1,407)   (1,961)   (3,094)   (4,096)
Impairment of intangible assets   —    —    (13,533)   — 
Loss from operating activities   (2,292)   (2,529)   (18,209)   (5,619)
                 
Foreign exchange (loss) gain   (1)   (8)   (15)   3 
Change in fair value of derivative warrant liabilities   —    1,427    —    940 
Interest and other income, net   154    172    295    375 
Total other income, net   153    1,591    280    1,318 
Loss before income tax benefit   (2,139)   (938)   (17,929)   (4,301)
                 
Income tax benefit   8    —    8    — 
                 
Net loss and total comprehensive loss   (2,131)   (938)   (17,921)   (4,301)
                 
Basic and diluted loss per share  ($0.11)  ($0.06)  ($0.96)  ($0.27)
                 
Weighted-average number of shares outstanding   20,116,776    15,924,522    18,701,159    15,924,522 




FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Grace Therapeutics' quarterly financial results for September 30, 2026?

Grace Therapeutics reported a $2.131 million net loss, or $0.11 per share, for the three months ended September 30, 2026. The year-earlier net loss was $938,000, or $0.06 per share. Quarterly operating loss narrowed to $2.292 million from $2.529 million.

When will Grace Therapeutics resubmit the GTx-104 application to the FDA?

Resubmission timing depends on which manufacturing pathway reaches readiness first, and either manufacturer, or both, may support the application. The current manufacturer has submitted a corrective action plan. Its reinspection depends on manufacturing readiness and FDA scheduling; transfer to a second, U.S.-based manufacturer has begun.

Keep reading